{
  "story_id": "f60a596eedc4c17db42203ceafd3f2ed",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-11-18T14:26:04.000Z",
  "content_hash": "1b95457d0d7c058a3cec1beea8e05f89201128036e1d5cba571945f0729287cc",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "MSD halts Phase III BELLWAVE-011 trial of nemtabrutinib for blood cancers",
    "dek": "MSD discontinues Phase III BELLWAVE-011 trial of nemtabrutinib for leukaemia and other haematologic malignancies",
    "prose": "Following an exhaustive evaluation of the complete dataset, the company confirmed the safety assessment, deciding to permanently halt the Phase III BELLWAVE-011 clinical investigation. [^1]\n\nMSD has discontinued its Phase III BELLWAVE-011 trial assessing nemtabrutinib (MK-1026) for leukaemia and other haematologic malignancies after an external Data Monitoring Committee (eDMC) review. [^2] The decision consequently led MSD to terminate its wider BELLWAVE clinical development programme, which includes two additional Phase III trials, BELLWAVE-008 (NCT05624554) and BELLWAVE-010 (NCT05947851). [^3] The eDMC reviewed trial data and advised that the clinical advantages offered by the candidate might fail to surpass the observed patient risks. [^4]\n\nMerck plans to stop development of its experimental blood cancer drug, nemtabrutinib, after a review found the benefits may not outweigh the risks. [^5] Some GOP lawmakers had reservations about Overton, a preventive care doctor who served in the Trump White House, due to her support for scaling back vaccine recommendations, her role in loosening restrictions on vapes, and her stance on abortion policy. [^6] The Trump administration is pulling the nomination of Heidi Overton to lead the U.S. Food and Drug Administration over concerns that she lacked support to get confirmed by the Senate. [^7]\n\nThe decision ends a broader development program for treating chronic lymphocytic leukemia and small lymphocytic lymphoma, including two other late-stage trials. [^8]",
    "cited": "[{\"statement\":\"Following an exhaustive evaluation of the complete dataset, the company confirmed the safety assessment, deciding to permanently halt the Phase III BELLWAVE-011 clinical investigation.\",\"source\":\"Clinical Trials Arena\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-18T09:44:56.000Z\",\"publisher_count\":1,\"sources\":[\"Clinical Trials Arena\"],\"url\":\"https://www.clinicaltrialsarena.com/news/msd-discontinues-bellwave-011-trial-nemtabrutinib/\"},{\"statement\":\"MSD has discontinued its Phase III BELLWAVE-011 trial assessing nemtabrutinib (MK-1026) for leukaemia and other haematologic malignancies after an external Data Monitoring Committee (eDMC) review.\",\"source\":\"Clinical Trials Arena\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-18T09:44:56.000Z\",\"publisher_count\":1,\"sources\":[\"Clinical Trials Arena\"],\"url\":\"https://www.clinicaltrialsarena.com/news/msd-discontinues-bellwave-011-trial-nemtabrutinib/\"},{\"statement\":\"The decision consequently led MSD to terminate its wider BELLWAVE clinical development programme, which includes two additional Phase III trials, BELLWAVE-008 (NCT05624554) and BELLWAVE-010 (NCT05947851).\",\"source\":\"Clinical Trials Arena\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-18T09:44:56.000Z\",\"publisher_count\":1,\"sources\":[\"Clinical Trials Arena\"],\"url\":\"https://www.clinicaltrialsarena.com/news/msd-discontinues-bellwave-011-trial-nemtabrutinib/\"},{\"statement\":\"The eDMC reviewed trial data and advised that the clinical advantages offered by the candidate might fail to surpass the observed patient risks.\",\"source\":\"Clinical Trials Arena\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-18T09:44:56.000Z\",\"publisher_count\":1,\"sources\":[\"Clinical Trials Arena\"],\"url\":\"https://www.clinicaltrialsarena.com/news/msd-discontinues-bellwave-011-trial-nemtabrutinib/\"},{\"statement\":\"Merck plans to stop development of its experimental blood cancer drug, nemtabrutinib, after a review found the benefits may not outweigh the risks.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-18T14:26:04.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"],\"url\":\"https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss\"},{\"statement\":\"Some GOP lawmakers had reservations about Overton, a preventive care doctor who served in the Trump White House, due to her support for scaling back vaccine recommendations, her role in loosening restrictions on vapes, and her stance on abortion policy.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-18T14:26:04.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"],\"url\":\"https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss\"},{\"statement\":\"The Trump administration is pulling the nomination of Heidi Overton to lead the U.S. Food and Drug Administration over concerns that she lacked support to get confirmed by the Senate.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-18T14:26:04.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"],\"url\":\"https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss\"},{\"statement\":\"The decision ends a broader development program for treating chronic lymphocytic leukemia and small lymphocytic lymphoma, including two other late-stage trials.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-18T14:26:04.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"],\"url\":\"https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss\"}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": {
    "slice_hash": "712a7eb3f6766b1a0886fad43dac52b5875aca3a15358f5f07e66c45dfe25a3c",
    "cursor_from": "ingest:raw_newsroomfloor.stories:712a7eb3f6766b1a",
    "cursor_to": "ingest:raw_newsroomfloor.stories:712a7eb3f6766b1a",
    "view": "ingest:raw_newsroomfloor.stories",
    "view_version": "1",
    "row_count": 1,
    "hash_basis": "sha256 over the JSON array of {insertId, json} rows as received (normalized wire shape), computed before the BigQuery forward",
    "credits": 0.01,
    "price_per_100_rows_written": 1,
    "sig": "UkagLgoWgyTm_OCf2u4gbgf3JBMBrBqVEW45Dfq4fYDSmDBbYpzqnZURwxq6UIfkZnf70HIWQkeHhxoyYNBqAQ",
    "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
    "signer_path": "lakehouse/data-extract/v1",
    "alg": "Ed25519",
    "signed": true
  },
  "receipt_note": "the ingest door's signed receipt for this revision, verbatim as the door returned it",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "d5e7eac532f2391ee124ed5c9d0641d1",
      "thread_id": "cd7a3a850eafa628f012363c726e51d8",
      "thread_label": "nemtabrutinib",
      "novelty": "UPDATE",
      "content_hash": "b76feeb1522ca30e40c49249c832f1c07b834601c8324ced84964b60c1f3005e",
      "compose": 3,
      "last_published_at": "2026-11-18T14:26:04.000Z",
      "read_receipt": {
        "slice_hash": "218f088f67fa000dc0fbc8fdd2ee6f1b5d0a34ad9721face19311fc3fcd41903",
        "cursor_from": "eyJ0cyI6IjIwMjYtMTEtMThUMTM6NDc6MDQuMDAwWiIsImlkIjoiYjJmNDc0Y2U5MGJmMzJiNzIwODA5MmRhZDIyMjk0OTUiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMTEtMThUMTU6Mzg6MjYuMDAwMDAwWiIsImlkIjoiOWE2NTExNGNmMTBmYjg4M2ZhNzY0MTM4NmU0OWNkZGYiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 3577351,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "Lykaf-PhO6r60RvvINpmnX97V3_53aW_ShFps9QcEbcgHStCZsHb89sEwDBnD54eBhr4HNif-ZS45SvRRSrVBg",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      },
      "landing": "air"
    },
    "written_at": "2026-11-19T21:23:15.232Z"
  },
  "cited_facts": [
    {
      "n": 1,
      "statement": "Following an exhaustive evaluation of the complete dataset, the company confirmed the safety assessment, deciding to permanently halt the Phase III BELLWAVE-011 clinical investigation.",
      "source": "Clinical Trials Arena",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.clinicaltrialsarena.com/news/msd-discontinues-bellwave-011-trial-nemtabrutinib/",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 2,
      "statement": "MSD has discontinued its Phase III BELLWAVE-011 trial assessing nemtabrutinib (MK-1026) for leukaemia and other haematologic malignancies after an external Data Monitoring Committee (eDMC) review.",
      "source": "Clinical Trials Arena",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.clinicaltrialsarena.com/news/msd-discontinues-bellwave-011-trial-nemtabrutinib/",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 3,
      "statement": "The decision consequently led MSD to terminate its wider BELLWAVE clinical development programme, which includes two additional Phase III trials, BELLWAVE-008 (NCT05624554) and BELLWAVE-010 (NCT05947851).",
      "source": "Clinical Trials Arena",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.clinicaltrialsarena.com/news/msd-discontinues-bellwave-011-trial-nemtabrutinib/",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 4,
      "statement": "The eDMC reviewed trial data and advised that the clinical advantages offered by the candidate might fail to surpass the observed patient risks.",
      "source": "Clinical Trials Arena",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.clinicaltrialsarena.com/news/msd-discontinues-bellwave-011-trial-nemtabrutinib/",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 5,
      "statement": "Merck plans to stop development of its experimental blood cancer drug, nemtabrutinib, after a review found the benefits may not outweigh the risks.",
      "source": "STAT",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 6,
      "statement": "Some GOP lawmakers had reservations about Overton, a preventive care doctor who served in the Trump White House, due to her support for scaling back vaccine recommendations, her role in loosening restrictions on vapes, and her stance on abortion policy.",
      "source": "STAT",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 7,
      "statement": "The Trump administration is pulling the nomination of Heidi Overton to lead the U.S. Food and Drug Administration over concerns that she lacked support to get confirmed by the Senate.",
      "source": "STAT",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 8,
      "statement": "The decision ends a broader development program for treating chronic lymphocytic leukemia and small lymphocytic lymphoma, including two other late-stage trials.",
      "source": "STAT",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss",
      "occurred_at": null,
      "published_at": null
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true. The dates on cited_facts (occurred_at, published_at) are the forge's, joined at read time; they are not part of the signed basis above."
}